Rally In AcelRx Gets More Intense On Recent Phase III Data
Lately there’s been a lot of positive sentiment propping up shares of AcelRx (NASDAQ: ACRX), which has moved up about 40% in the last five trading sessions. This recent move brings YTD returns of the...
View ArticleACADIA Investors Await Clinical Trial Results For Pimavanserin
Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) have recently given back a lot of the gains that were made earlier in the year – especially those from September, to bring total YTD gains to 99%. With...
View ArticleClik here to view.
Exelixis Traders Brace For Upcoming FDA Decision
Many biotech traders and investors are excited, and maybe a bit anxious about the upcoming PDUFA action date for Exelixis’ (NASDAQ: EXEL) cabozantinib in the treatment of Medullary Thyroid Cancer...
View Article3 Superactive Bio Stocks (November 26, 2012)
Hello, after a week-long break we’re back with the superactive bio stock updates. Here are three from today. 1.) Celsion Corp (NASDAQ: CLSN) jumped over 17% today on increasingly bullish reports from...
View Article3 Superactive Bio Stocks (November 27, 2012)
Very interesting trading day. Here are 3 tickers that saw an extremely high level of activity 1.) ACADIA Pharmaceuticals (NASDAQ: ACAD) released the much-anticipated results for their drug pimavanserin...
View ArticleAcadia Rockets Into The Stratosphere On Clinical Trial Data
Yesterday morning we finally got to see the much anticipated data for ACADIA Pharmaceuticals’ (NASDAQ: ACAD) phase III trial, which tested its flagship drug pimavanserin in the treatment of Parkinson’s...
View Article3 Superactive Bio Stocks (November 28, 2012)
Here are three bio stocks that saw abnormally high activity in today’s trading. 1.) Acadia Pharmaceuticals (NASDAQ: ACAD) remained an extremely hot topic today after the company posted phase III...
View ArticleInterMune Gearing Up For Another Round With The FDA
After spending the last few months in a well-defined trading range of $8-10 per share, the pulmonary fibrosis drug development company InterMune (NASDAQ:ITMN) has settled right in the middle (at...
View Article3 Superactive Bio Stocks (November 29, 2012)
Here are 3 tickers from healthcare that saw big activity today 1.) Exelixis (NASDAQ: EXEL) saw a lot of activity, but not much movement in stock price despite an FDA approval of cabozantinib for the...
View Article3 Superactive Bio Stocks (November 30, 2012)
Here are your 3 to wrap up the week 1.) Amarin Corporation (NASDAQ: AMRN) longs are still anticipating a buyout for the most part, although the launch date of Vascepa draws closer (Q1 2013). The stock...
View ArticleNPS Pharma Drifts Higher On Potential Orphan Drug Approval
NPS Pharmaceuticals (NASDAQ: NPSP) is one of the many biotech stocks that has given its shareholders exceptionally large returns this year. The Utah-based company has a diverse pipeline that contains...
View Article3 Superactive Bio Stocks (December 3rd, 2012)
Welcome to the last month of 2012! Here are three bio stocks that saw high activity in today’s trading. 1.) Amarin (NASDAQ: AMRN) continued to ride on recent momentum that was build on additional...
View ArticleDARA Biosciences Seeks Orphan Drug Status For KRN5500
DARA Biosciences (NASDAQ: DARA) drew a lot of attention from the market after a press release on January 17, 2012 that announced the official “acquisition” of the private, South Carolina-based...
View Article3 Superactive Bio Stocks (December 5, 2012)
Here are 3 stocks that saw big activity today 1.) Neuralstem (NADSAQ: CUR) moved down 19.46%, likely due to a fresh round of analyst reports (ValuEngine, Reuters, New Constructs) released yesterday....
View ArticleStrong Fundamentals Support A Future Recovery In Questcor
Questcor Pharmaceuticals (NASDAQ: QCOR) has been a particularly speculative investment in the biotech sector after September 19th 2012, when the healthcare company Aetna changed its insurance policy...
View ArticleRally In Celsion Continues On Upcoming HEAT Study Results & SPA Declaration...
We’ve seen a lot of exceptional performance in biotech stocks this year, especially in oncology drug development companies. One company that has been building significant momentum in recent trading is...
View Article3 Superactive Bio Stocks (December 5, 2012)
This week is getting more interesting by the trading day, isn’t it? Anyway, here are three bio stocks that saw big action today 1.) Amarin (NASDAQ: AMRN) gave back 4.44% of its prolonged rally, which...
View ArticlePositive Hints on Phase III Trial Causes Cyclacel To Recover Losses Quickly
After seeing a temporary break of its bullish momentum in November’s trading, Cyclacel Pharmaceuticals (NASDAQ: CYCC) is heating up again as the market digests the latest results gathered from the...
View Article3 Superactive Bio Stocks (December 6, 2012)
Here are 3 stocks that saw big action today 1.) Amarin (NASDAQ: AMRN) was essentially flat for most of the day, but is down an alarming 21% in after hours trading on this press release. Besides the...
View Article3 Superactive Bio Stocks (December 7, 2012)
Here are 3 bio stocks that saw heavy activity as we closed out the week 1.) Amarin (NASDAQ: AMRN) saw abnormally high amounts of activity, despite the notion that it’s already the most speculated and...
View Article
